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Induction of Terminal Differentiation in Melanoma
Cells on Downregulation of b-Amyloid Precursor
Protein
Michelle G. Botelho1, Xiaolei Wang2, Donna J. Arndt-Jovin1, Dorothea Becker2 and Thomas M. Jovin1
The incidence of melanoma, the most aggressive type of skin cancer, is increasing dramatically, and an effective
treatment for patients with advanced disease is as yet unavailable. Greater insight into the molecular features of
primary and metastatic melanoma is required, particularly the identification of key regulatory genes that shield
the tumor cells from terminal differentiation and apoptosis. The b-amyloid precursor protein (APP) is a cell
surface receptor and the transmembrane precursor of the Ab-peptide, which has an important role in
Alzheimer’s disease. The study presented here provides evidence that APP is expressed at high levels in
advanced-stage melanomas, and that the cells cleave APP and secrete sAPP. We show that blocking the
expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their
terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell
line renders the cells susceptible to several chemotherapeutic agents. Targeting APP may thus constitute a new
approach to the treatment of this disease.
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INTRODUCTION
Despite intense efforts at prevention, the worldwide inci-
dence of melanoma has nearly quadrupled over the past
25 years and continues to rise. The stages defining melanoma
progression are atypical nevi, melanoma in situ, primary
melanoma in the radial growth phase, primary melanoma in
the vertical growth phase (VGP), and melanoma in the
metastatic growth phase (MGP). The clinical prognosis for
patients with melanoma is directly related to the size and
depth of invasion at the time of diagnosis. That is, if detected
at an early stage, the patient is often cured by a wide and
deep excision of the tumor. However, once melanoma
metastasizes, the prognosis is poor because neither che-
motherapy nor radiation treatment alters the course of the
disease. For this reason, it is imperative to identify and
characterize key regulatory genes that can serve as targets for
molecular therapy.
The b-amyloid precursor protein (APP) is a ubiquitous
type I transmembrane protein (Kang et al., 1987) with a large
extracellular segment. APP has alternatively spliced isoforms,
of which the predominant non-neuronal forms, APP751 and
APP770, span 751 and 770 amino acids, respectively, and
contain a Kunitz-type inhibitor domain (Kitaguchi et al.,
1988; Ponte et al., 1988; Tanzi et al., 1988). APP has a major
role in the pathogenesis of Alzheimer’s disease, and
mutations in its primary sequence cause presenile cases of
this very prevalent neurodegenerative disease. The trans-
membrane protein is constitutively cleaved by several
proteases, collectively denominated a-secretase, at a site
in the extracellular domain of APP located 13 residues
N-terminal to its membrane insertion point (Lammich et al.,
1999). Alternative amyloidogenic processing by b-secretase
in neurons leads to the production of the Ab-peptide that
constitutes the predominant component of amyloid plaques
in the cerebral cortex of Alzheimer patients (Annaert and
De Strooper, 2002). Processing of APP by either a- or
b-secretases also releases into the extracellular space, a large
soluble ectodomain fragment, denoted as secreted APP
(sAPPa and sAPPb, respectively).
The extracellular segment of the APP molecule and thus,
its secreted form as well, encompasses an N-terminal growth
factor-like domain (Rossjohn et al., 1999), metal-binding
motifs (Bush et al., 1993; Kong et al., 2007), two heparan
sulfate-binding sites (Narindrasorasak et al., 1991; Small
et al., 1994), and a RERMS sequence with putative growth-
promoting properties (Ninomiya et al., 1993; Li et al., 1997).
These different motifs, and their presumed interaction
partners, confer a variety of physiological functions on sAPP,
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many of which are still obscure. Indeed, it has been shown
that sAPP induces cell proliferation and neurite outgrowth, as
well as exerting a general neuroprotective effect (reviewed in
Gralle and Ferreira, 2007).
Previous studies have shown that APP and sAPP have a
role in the proliferation (Hoffmann et al., 2000) and move-
ment of epidermal keratinocytes (KCs), to which sAPP binds
(Hoffmann et al., 1999). In addition, sAPP increases the
migration velocity, frequency of lamellipodial protrusion,
and ruffle formation of KCs (Kirfel et al., 2002). These
processes are important in wound healing, and it has been
reported that both the expression of APP and secretion of
sAPP increase after skin damage (Kummer et al., 2002). In
addition, KCs from APP/APP-like protein 2-deficient mice
exhibit reduced proliferation, migration, and adhesion
(Siemes et al., 2006). Other important functions of sAPP in
the skin are cytoprotection and inhibition of apoptosis,
induced by UV-B light or serum deprivation (Wehner et al.,
2004). Furthermore, exposure of the A375 melanoma cell
line to sAPP increases lamellipodial movement and melanin
secretion (Quast et al., 2003).
In a previously whole-genome microarray analysis of
nevus and melanoma tissue samples (Smith et al., 2005),
some of the probe sets for APP provided an initial indication
that the gene might be expressed at higher levels in VGP and
MGP melanomas compared with nevi and melanoma in situ
(D Becker, unpublished data). In the present study, we
determined the level of APP expression in and sAPP binding
to cell lines established from advanced-stage melanomas.
APP was expressed at high levels in VGP and MGP
melanoma cells and was cleaved, leading to secretion of
sAPP. Suppressing the expression of APP by small interfering
RNAs (siRNAs) induced melanoma-cell differentiation, char-
acterized by a dramatic change to a prominent dendritic cell
phenotype. It also led to upregulation of some melanocyte
pigmentation/lineage markers, and to a slight but noticeable
decrease in expression of the ABCB5 protein, a member of
the ATP-binding cassette (ABC) transporter superfamily,
which has been implicated in the chemoresistance of
melanoma cells (Schatton et al., 2008). Furthermore, in the
case of a metastatic melanoma cell line, inhibition of APP
expression sensitized the cells to different chemotherapeutics
drugs. Given these findings, we postulate that APP is a crucial
gatekeeper of melanoma-cell differentiation participating in
the maintenance of this disease, and that the targeting of APP
may represent a previously unreported approach to treating
advanced melanoma.
RESULTS
Increased APP expression correlates with progression to
advanced melanoma
To determine the level of expression of APP in the different
stages of melanoma progression, we probed cryopreserved
tissue samples, ranging from normal human skin to melano-
ma-infiltrating lymph nodes, using an antibody (Ab) to APP
(Figure 1). In normal skin, expression of APP was detected in
some dermal fibroblasts but not in melanocytes of the
epidermal/dermal junction. Likewise, nevocytes, which are
clusters of melanocytes, did not express APP, either in benign
or in atypical nevi. In melanomas in situ, APP expression was
Normal skin Benign nevus
VGP melanoma MGP melanoma Melanoma-infiltratedlymph node
Atypical nevus
Figure 1. Amyloid precursor protein (APP) expression in cryopreserved tissue sections of vertical growth phase (VGP) and metastatic growth phase
(MGP) melanomas. Samples of normal skin, benign and atypical nevi, VGP melanoma, MGP melanoma, and a melanoma-infiltrated lymph node, were
probed with an antibody to APP (P2-1), and counterstained with hematoxylin. Images were white balanced, such that the average background color in
each image is the same. Scale bar¼ 50 mm.
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barely detected (data not shown). In contrast, APP expression
levels were high in VGP melanomas, in visceral and
subcutaneous metastases, and in melanoma-infiltrated lymph
nodes, suggesting that progression from melanoma in situ to
advanced melanoma is accompanied by upregulation of APP.
We also performed immunofluorescence analysis of APP in
melanoma cells derived from a VGP and three different MGP
melanomas, which in every case revealed strong perinuclear
staining of APP (Figure 2). Interestingly, the highest level of
APP expression was detected in MGP3, a cell line that has all
the features of very aggressive melanoma.
Differential APP expression and sAPP secretion
in melanoma cells
We performed reverse transcription PCR analysis of the four
melanoma cell lines with primers spanning from exons 6 to
10 of APP, the region in which APP is alternatively spliced
(Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988).
The results revealed the presence of the two predominant
non-neuronal APP isoforms, APP770 and APP751, in each of
the cell lines (Figure 3a), with MGP3 showing the most
elevated expression of the APP770 isoform. In addition, all
four cell lines secreted sAPP (Figure 3b), as determined by
immunoblot analysis of their conditioned supernatant culture
media using an Ab to the N-terminal domain of APP
(Figure 3b). Purified, recombinant human sAPPa695 served
as an internal standard for quantification of the sAPP
produced by each cell line (Figure 3c). As with APP
expression, the highly aggressive cell line, MGP3, secreted
higher levels of sAPP compared with the VGP and the other
less aggressive cell lines, MGP1 and MGP2.
sAPP binding to melanoma cells assessed with
quantum dot probes
For sAPP to exert an autocrine and/or paracrine proliferative
effect, it must not only be secreted but also (re)bind to cells.
To determine sAPP binding, purified, recombinant human
sAPPa770 was biotinylated and coupled to streptavidin-
coated quantum dots (QDs) emitting at 605 nm (Figure 4a).
These extremely fluorescent and photostable nanoparticles
are excellent probes for binding and trafficking events
associated with cellular signaling and function (Alivisatos
et al., 2005). The different melanoma cell lines were seeded
on cover slips and examined with confocal microscopy after
the addition of 2 nM sAPPa770–QD605. After 10minutes, a
distinct binding of sAPPa770–QD605 to the melanoma cells
was detected (Figure 4b), with the highest levels in MGP3, in
which certain areas of the cell membrane showed a higher
density of the complexes. The level of binding was quantified
by flow cytometry (Figure 4c). For this purpose, cells were
incubated with 2 nM sAPPa770–QD605 using unconjugated
QD605 as a control. The binding of sAPPa770–QD605
correlated with the level of expressed APP. That is, cells that
produced more APP also bound more sAPP. Nonspecific QD
binding was not detected. The addition of sAPPa770 to the
melanoma cells also led toB30–40% increase in cell number
determined at 72 hours of incubation (Supplementary
Figure S1). The increase was maximal in the presence of 3
and 10 nM sAPPa770 in the case of the VGP and MGP2 lines,
respectively, with the smallest effect on MGP1 and MGP3. It
is likely that the relatively small stimulatory effect of
exogenously added sAPP on melanoma cell proliferation
was due to of the presence of significant levels of sAPP
already produced and secreted by the cells.
Downregulation of APP expression by RNA interference
leads to reduced cell proliferation
We downregulated the expression of APP by transfecting
MGP2 cells with APP-specific siRNAs. Cells receiving non-
targeting siRNAs or only transfection reagent served as
controls. At 96 hours posttransfection, the APP siRNA-
transfected cells displayed not only a reduction in
cell number but also two very prominent phenotypic
changes: an irregular cell shape and formation of long
VGP MGP1 MGP2 MGP3
Figure 2. Amyloid precursor protein (APP) expression in vertical growth phase (VGP) and metastatic growth phase (MGP) melanoma cells. Cells from a
VGP and three different MGP melanoma cell lines (MGP1, MGP2, and MGP3) were analyzed by standard immunofluorescence with an antibody to APP
(22C11). (a) Images of the APP antibody-stained melanoma cells captured using a 25 objective. Scale bar¼ 20 mm. (b) Images of single melanoma cells.
Scale bar¼ 20 mm.
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dendrites (Figure 5a and 5b). In addition, a significant fraction
of the cells exhibited signs of apoptosis. That these observed
morphological changes were indeed the result of the blocked
expression of APP was confirmed by immunofluorescence.
At 90 hours posttransfection, APP protein levels were lower
in the APP siRNA-transfected MGP2 melanoma cells com-
pared with the controls (Figure 5c). Furthermore, at 48 hours
posttransfection, the APP770 and the APP751 isoform
transcripts were reduced by 80% and 75%, respectively
(Figure 5d). We tentatively attribute the closely migrating APP
proteins of 90 and 110 kD, which were detected in the
control cell lysates (Figure 5e), to differential posttranslational
glycosylation. After transfection with APP siRNAs, the
expression of both proteins decreased (Figure 5e).
The impact of APP downregulation on melanoma cell
proliferation was determined with a chemoluminescent
cell-viability assay. At 120 hours posttransfection, there was
a 50% reduction in cell number of the APP siRNA-treated
MGP2 cell compared with the cells that received only the
transfection reagent, and a 40% reduction in comparison
with cells transfected with control siRNA (Figure 5f). This
reduction in cell number could be counteracted to a signi-
ficant extent by the addition of sAPPa770 (data not shown).
Downregulation of APP also led to a decrease in cell number
of the MGP1 and MGP3 lines. However, a concomitant
formation of long dendrites (arrow heads, Supplementary
Figure S2a) was noted, particularly in the MGP1 cells.
To determine whether the observed differentiation of the
melanoma cells was irreversible or only temporary, we
analyzed an APP siRNA-treated sample 15 days after
transfection, at which time, the acute effect of siRNA
transfection would have disappeared (Bradbury, 2005).
However, the elongated, differentiated cells persisted (Figure
6a), from which we conclude that after the onset of terminal
differentiation by transfection using a single dose of APP
siRNA, the melanoma cells do not revert to an undiffer-
entiated phenotype.
Downregulation of APP leads to upregulation of melanocyte
pigmentation/differentiation markers
To determine whether these overt morphological changes
were accompanied by a change in melanocyte lineage-
specific differentiation markers, we performed immunofluor-
escence and immunoblot analysis using antibodies to human
tyrosinase, tyrosinase-related protein-1 (TRP1) (Ando et al.,
2007), and microphthalmia-associated transcription factor
(MITF) (Zhuang et al., 2007). We detected a significant
increase in the expression of tyrosinase, TRP1, and MITF in
the APP siRNA-transfected cells (Figure 6b), which interest-
ingly were highest in cells that had assumed the most
dendritic phenotype. The strong increase in tyrosinase and
TRP1 expression (Figure 6c) was confirmed by immunoblot
analysis of cell lysates prepared from the same APP siRNA-
transfected melanoma cells.
Downregulation of APP leads to a decrease of the
chemoresistance marker, ABCB5, and sensitivity to
chemotherapy drugs
The doxorubicin-resistant transporter, ABCB5, has been
described as a marker of melanoma-initiating cells (Schatton
et al., 2008). We investigated whether the downregulation of
APP affects the expression level of this marker. Immunofluo-
rescence and immunoblot analysis of melanoma cells trans-
fected with APP siRNA revealed a small but noticeable
decrease in ABCB5 expression compared with cells that were
not transfected or transfected with control siRNA (Figure 6b
and c).
To determine whether downregulation of APP would
sensitize the melanoma cells to the action of cytotoxic
drugs such as doxorubicin, paclitaxel, and temozolomide to
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Figure 3. Amyloid precursor protein (APP) mRNA expression and secreted
APP (sAPP) secretion by melanoma cell lines. (a) Reverse transcription PCR
analysis with exon 6 and exon 10 APP-specific primers of mRNA from the
vertical growth phase (VGP) and the metastatic growth phase 1 (MGP1),
MGP2, and MGP3 melanoma cells reveals two APP isoform-specific
transcripts (APP770 and APP751) of 470 and 410bp, respectively. (b) Secretion
of sAPP into the media by VGP, and MGP1, MGP2, and MGP3 melanoma
cells, cultured for 90 hours under serum-free conditions. sAPP was detected
by immunoblot analysis of the conditioned media using an antibody to
APP (22C11). Purified, recombinant human sAPPa695 (55, 28, and 11nM) was
used as an internal standard for quantification of sAPP secreted by the
melanoma cells. (c) Quantification of the amounts of sAPP detected by
the respective immunoblot analysis, means±SD; Student’s t-test: *Po0.05;
**P¼0.00007 (compared with VGP) ***P¼0.0004 and ****P¼ 0.011
(compared with MGP3).
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which melanomas are refractory, MGP3 cells were trans-
fected with APP siRNA, non-targeting siRNA, or only
transfection reagent. At 96 hours posttransfection, the cells
were treated for 12 hours with 2 mM paclitaxel, 10 mM
doxorubicin, or 200 mM temozolomide. Cell survival was
determined by a chemoluminescence cell viability assay.
Compared with the controls, the cells transfected with APP
siRNA, followed by addition of doxorubicin, paclitaxel, or
temozolomide, exhibited a B20–40% decrease in cell
number (Figure 7).
DISCUSSION
Over the past decade, a major focus of melanoma research
has been on gaining an understanding of why advanced
melanoma cells are shielded from apoptosis and, as part of
this phenomenon, from undergoing terminal differentiation.
The findings presented here establish that the APP gene,
which has a pertinent role in Alzheimer’s disease, is
expressed at high levels in VGP and MGP melanomas, in
contrast to little or no expression of APP in the benign and
atypical nevi and in melanomas in situ. This suggests that the
expression of the APP gene is induced during the progression
from early to advanced melanoma. Although only a detailed
analysis of nevus - melanoma progression tissue micro-
arrays will provide a definite answer as to whether or not the
status of APP expression qualifies this gene as a bona fide
progression marker of this malignancy, reports in the
scientific literature have documented an upregulation of
APP in glioblastoma, in oral squamous cell carcinoma, and in
thyroid, pancreatic, and colon cancer (Meng et al., 2001;
Hansel et al., 2003; Ko et al., 2004; Culicchia et al., 2008;
Krause et al., 2008).
The second and equally important finding of our study is
that blocking the expression of APP in VGP and MGP
melanoma cells causes their terminal and irreversible
differentiation, and that this dramatic change in cell
morphology is accompanied by an increase in well-char-
acterized melanocyte pigmentation/differentiation markers,
such as TRP1 and MITF. Although it is has been shown that
melanoma cells can be induced to differentiate upon
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Figure 4. Binding of sAPPa770–QD605nm complex to melanoma cells. (a) Coupling of purified, biotinylated recombinant human secreted amyloid precursor
protein a770 (sAPPa770) to streptavidin-coated quantum dots emitting at 605 nm (QD605nm) (ratio of three sAPPs per QD). (b) Vertical growth phase (VGP) and
metastatic growth phase (MGP) melanoma cells, incubated with the sAPPa770–QD605nm complex, imaged by confocal microscopy. Orange color:
sAPPa770–QD605nm fluorescence overlayed on DIC images. Scale bar¼ 10 mm. (c) Fluorescent-activated cell sorting analysis of fluorescence emission of
melanoma cells incubated with the APPa770–QD605nm complex (black); melanoma cells incubated with QD605nm alone (red) (nonspecific binding); melanoma
cells not incubated with either the complex, or QD605nm alone (green).
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exposure to some select, external compounds, there has been
little information regarding signaling pathways or individual
genes that by virtue of functioning as pertinent gatekeeper(s)
prevent VGP and MGP melanoma cells from undergoing
terminal differentiation. This observation, in turn links to our
third finding that blocking the expression of APP renders
the tumor cells susceptible to the action of three cytotoxic
agents to which melanoma is resistant. Fourth, we show
that advanced-stage melanoma cells not only express
APP but also cleave, secrete, and bind sAPP, raising the
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Figure 5. Differentiation of melanoma cell after downregulation of amyloid precursor protein (APP). (a) Wide-field images of metastatic growth phase 2
(MGP2) melanoma cells non-transfected, or transfected with control or APP small interfering RNAs (siRNAs) at day 5 posttransfection. Scale bar¼ 50 mm.
(b) Immunohistochemistry analysis of the non-transfected or siRNA-transfected MGP2 melanoma cells using an antibody to tubulin. Scale bar¼ 10mm.
(c) Immunohistochemistry analysis of the same cells with an antibody to APP (P2-1). Scale bar¼ 50 mm. (d) Reverse transcription PCR analysis of the non-
transfected and siRNA-transfected MGP2 melanoma cells reveals downregulation of the APP770 and APP751 isoform transcripts in only the APP siRNA-
transfected MGP2 melanoma cells. (e) Immunoblot analysis of the same cells with an antibody to APP (22C11). APP is present in the non-transfected and control
siRNA-transfected MGP2 melanoma cells, but not in the APP siRNA-transfected MGP2 melanoma cells. (f) Cell viability at 120 hours after siRNA transfection.
Non-transfected, non-targeting control, and APP siRNA-transfected MGP2 melanoma cells were analyzed for their ATP content by a luminescence assay,
means±SD; Student’s t-test: *P¼0.071; **P¼ 0.0012; ***P¼ 0.0064.
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possibility that by acting as a paracrine signal, sAPP
stimulates the melanoma microenvironment. Such a signaling
circuit would be similar to that associated with the
stimulatory effect exerted by sAPP on the proliferation and
migration of epidermal KCs (Hoffmann et al., 2000; Kirfel
et al., 2002).
Several studies have shown that APP regulates the
transcription of certain genes through its intracellular domain
(APP intracellular domain, AICD) (Kim et al., 2003; von Rotz
et al., 2004; Telese et al., 2005; Zhang et al., 2007; Belyaev
et al., 2009). This regulation involves the binding of the AICD,
when released from transmembrane APP, to adaptor proteins,
such as Fe65 and Jip1b, and to a nuclear docking protein, such
as TIP60 (von Rotz et al., 2004). The resulting signaling
complexes bind to promoter regions in the nucleus and
thereby regulate the expression of target genes. Of relevance to
skin cancers, including melanoma, is the observation that
AICD downregulates the expression of EGFR in KCs, which
affects the propensity for tumor formation in mice (Zhang
et al., 2007). Given our findings, one could hypothesize that
an analogous mechanism of AICD signaling is active in
melanoma cells, explaining why genes such as TRP1, MITF,
and tyrosinase are upregulated after suppression of APP.
With the VGP and MGP melanoma cell lines analyzed in
this study, we did not obtain evidence for an inverse
correlation between the level of APP expression and the
degree of pigmentation. Likewise, our immunoblot analyses
of APP siRNA-transfected melanoma cells did not show an
elevated (compared with the controls) expression of the
Notch-1 gene, which has an important role in proliferation,
differentiation, and cell death (Artavanis-Tsakonas et al.,
1999) (data not shown). However, these findings do not
exclude other mechanisms of regulation and/or interaction
between these two molecules, such as to produce a
disruption by Notch of the AICD-Fe65-Tip60 trimeric
complex (Kim et al., 2007), cross-talk between Notch and
APP at the plasma membrane (Fischer et al., 2005; Oh et al.,
2005), or competition between the two proteins for binding
to g-secretase (Lleo et al., 2003).
Lastly, in view of the fact that advanced melanoma is
refractory to chemotherapy, it is intriguing that the down-
regulation of APP in the MGP2 melanoma cells led to a
distinct reduction in the expression of the doxorubicin-
resistant ABC transporter, ABCB5, and along the same line,
sensitized the melanoma cells to doxorubicin, paclitaxel, and
temozolomide.
In summary, APP now represents the second gene that,
similar to FGFR-1 (Becker et al., 1992), shields VGP and MGP
melanoma cells from terminal differentiation. Although it
remains to be determined whether suppressing APP in human
melanoma xenografts leads to tumor growth arrest due to
irreversible cell differentiation and apoptosis, as in the case of
FGFR-1, our findings strongly support the view outlined in a
schematic summary (Figure 8); namely, that APP may con-
stitute an important new target for much needed previously
unreported and effective approaches to treat advanced
melanoma.
MATERIALS AND METHODS
Tissue accrual and immunohistochemistry
Tissue specimens, representing normal skin, were obtained
from patients with no clinical history of melanoma. Nevus,
melanoma in situ, and VGP and MGP melanoma tissue specimens
were obtained from patients with a clinical history of melanoma,
who had not undergone systemic treatment for their disease
before surgical resection of the lesions. All tissue samples were
obtained in compliance with approved clinical and institutional
review board protocols (Department of Pathology, University of
Pittsburgh). The study was conducted according to the declaration of
Helsinki principles. Patient consent for experiments was not
required, because the materials were obtained from the patho-
logy archive and were not collected prospectively for any
research study. Standard immunohistochemistry of the cryopre-
served, de-identified tissue samples was performed as described
(Wang et al., 1996), using a mouse mAb to APP (P2-1) (BioSource
International, Camarillo, CA), which recognizes a native epitope
of APP.
Melanoma cell lines and immunofluorescence
Vertical growth phase melanoma cell line, WM983-A (VGP), and
MGP melanoma cell lines, WM983-B (MGP1), WM1158 (MGP2),
Figure 6. Upregulation of pigmentation/differentiation markers and downregulation of the chemoresistance mediator, ABCB5, upon downregulation of
amyloid precursor protein (APP) in metastatic growth phase (MGP) melanoma cells. (a) Wide-field images of non-transfected MGP2 cells, or MGP2 transfected
with control or APP small interfering RNAs (siRNAs) at day 15 after transfection. Scale bar¼ 50mm. (b) Immunofluorescence of MGP2 melanoma cells not
transfected, or transfected with control or APP siRNAs. Cells were stained with antibodies to human tyrosinase, TRP1, MITF, or ABCB5. Scale bar¼50 mm.
(c) Immunoblot analysis of MGP2 melanoma cell lysates. MGP2 melanoma cells not transfected or transfected with non-targeting control or APP siRNAs were
analyzed at 96 hours after siRNA transfection with antibodies to human tyrosinase, TRP1, or ABCB5. Tubulin served as a loading control.
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Figure 7. Susceptibility of metastatic growth phase 3 cells to chemo-
therapeutic drugs after downregulation of amyloid precursor protein.
At 96 hours after small interfering RNA (siRNA) transfection, the non-
transfected, and the non-targeting control and APP siRNA-transfected MGP3
melanoma cells were incubated for 12 hours with no drug, or with paclitaxel,
doxorubicin, or temozolomide. ATP content, determined by a luminescence
assay, was used to establish cell numbers, means±SD; Student’s t-test:
*Po0.005; **Po0.05 (compared with no drugs).
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and WM852 (MGP3) were provided by Dr Meenhard Herlyn (The
Wistar Institute, Philadelphia, PA). The cells were propagated in vitro
as described (Becker et al., 1989). Immunofluorescence analysis of
the melanoma cells was undertaken with a murine mAb, which
recognizes an N-terminal epitope of APP (22C11) (Millipore/
Chemicon, Billerica, MA).
Metastatic growth phase 2 melanoma cells not transfected
or transfected with 100 nM APP or control siRNAs were seeded onto
cover slips, and fixed with 3.7% paraformaldehyde and permeabi-
lized with Triton X-100 96 hours posttransfection. The cells were
probed with antibodies to human tyrosinase (C-19, Santa Cruz
Biotechnology, Santa Cruz, CA), TPR1 (TA99, Santa Cruz Biotech-
nology), MITF (clone D5, Dako, Glostrup, Denmark), or ABCB5
(600-401, Rockland Immunochemicals, Gilbertsville, PA) followed,
in each case, by incubation with a Cy5-conjugated secondary Ab.
Cells were fixed with methanol for staining with the APP Ab (P2-1)
that binds to a native epitope of APP.
Reverse transcription PCR and analysis of sAPP secretion
Total mRNAs, isolated with an RNeasy kit (Qiagen, Hilden,
Germany), were analyzed using an OneStep reverse transcrip-
tion PCR kit (Qiagen). Collected conditioned media were subjec-
ted to immunoblot analysis. Purified recombinant human sAPPa695,
prepared as previously described (Gralle et al., 2002), was used to
calculate the amount of sAPP secreted by the melanoma cells. For
further details, see Supplementary Materials and Methods.
Determination of sAPPa770–QD605 complex binding to
melanoma cells
Purified, recombinant human sAPPa770 (Gralle et al., 2002) was
biotinylated using NHS-PEO4-biotin reagent (Thermo Scientific
Pierce, Rockford, IL). Additional details are provided in the
Supplementary Materials and Methods.
RNA interference assays and immunoblot analysis
A total of 100 nM of APP ON-TARGETplus SMARTpool siRNAs
or 100 nM control ON-TARGETplus non-targeting siRNAs
(Dharmacon, Lafayette, CO) were mixed with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) and transfected into WM983-B (MGP1),
WM1158 (MGP2), or WM852 (MGP3) melanoma cells, seeded
24 hours before transfection. Melanoma cells treated only with
Lipofectamine 2000 served as an additional control (untreated
sample).
Total cell lysates of melanoma cells transfected with APP or
control siRNAs, or only Lipofectamine 2000, were prepared 96 to
120 hours after siRNA transfection, and separated on NuPAGE
Novex system Bis-Tris 10% gel with MES (2-(N-morpholino)ethane-
sulfonic acid)–SDS-running buffer (Invitrogen). After transfer to
nitrocellulose membrane, the protein lysates were probed with an
Ab to APP (22C11), human tyrosinase, TRP1, or ABCB5, followed by
incubation with a horseradish peroxidase-conjugated secondary Ab,
and SuperSignal West Pico chemiluminescent reagent (Thermo
Scientific Pierce, Bonn, Germany). The nitrocellulose membrane
was stripped of the APP signal, and re-probed with a mouse mAb to
tubulin (a gift from Dr Mary Osborn).
Microscopy and image processing
Non-confocal images were acquired with a Zeiss LSM 510-Meta
system (Zeiss, Goettingen, Germany) using a 10 objective.
Confocal laser scanning microscopy was performed with the same
system, using 63 1.2 NA water immersion, 63 1.4 NA oil
immersion, or 25 NA 0.8 objectives. Wide-field epifluorescence
microscopy was performed using a Zeiss Axiovert microscope with a
10 objective. Differential interference contrast (DIC) images were
contrast adjusted and corrected for illumination field intensity
variations.
Flow cytometric analysis, and cell viability and cytotoxic drug
sensitivity assays
Melanoma cell lines, resuspended and incubated for 40minutes at
4 1C with 2 nM sAPPa770–QD605nm complex, were analyzed in a
Coulter Epics Elite flow cytometer (Beckman Coulter, Krefeld,
Germany) equipped with a 488 nm argon ion laser and a QD filter
605/40m.
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Figure 8. Scheme for the effect of downregulation of amyloid precursor protein (APP) in melanoma cells. APP maintains melanoma cells in an
undifferentiated proliferative state. Downregulation by RNA interference leads to terminal differentiation and apoptosis, manifested by the appearance of
elongated cells, with elevated differentiation markers and susceptibility to chemotherapeutic drugs. sAPP, secreted APP.
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At 48 hours after siRNA transfection, melanoma cells were
seeded, in quadruplicate, into 96-well plates. After 72 hours, the
number of viable cells was established using the CellTiter-Glo
luminescent cell-viability assay (Promega, Madison, WI). Lumines-
cence signals were measured on a Hidex Chameleon V plate reader
(Hidex, Turku, Finland). For the drug-sensitivity assay, cells, seeded
as described above, were treated for 12 hours with doxorubicin
(10 mM), paclitaxel (2 mM), or temozolomide (200mM) (Sigma-Aldrich,
Schnelldorf, Germany) 96 hours after siRNA transfection, and then
analyzed with the CellTiter-Glo luminescent cell-viability assay.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
MGB would like to thank Matthias Gralle (Department of Neuro- and Sensory
Physiology, University of Go¨ttingen, Germany) for help with the sAPP
expression, and for suggestions and critical review of the manuscript. We also
thank Wouter Caarls for assistance with DIC image correction. MGB was
supported by fellowships from the Alexander von Humboldt Foundation,
Fluoromag (EC contract no. 037465) and the DFG Research Center for
Molecular Physiology of the Brain (CMPB, Excellence Cluster EXC 171 – FZT
103 ‘‘Microscopy at Nanometer Range’’). This work was supported in part by
a grant from the National Institutes of Health to DB.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Alivisatos AP, Gu WW, Larabell C (2005) Quantum dots as cellular probes.
Annu Rev Biomed Eng 7:55–76
Ando H, Kondoh H, Ichihashi M, Hearing VJ (2007) Approaches to identify
inhibitors of melanin biosynthesis via the quality control of tyrosinase.
J Invest Dermatol 127:751–61
Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer0s
disease. Annu Rev Cell Dev Biol 18:25–51
Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate
control and signal integration in development. Science 284:770–6
Becker D, Lee PL, Rodeck U, Herlyn M (1992) Inhibition of the fibroblast
growth-factor receptor 1 (FGFR-1) gene in human melanocytes and
malignant melanomas leads to inhibition of proliferation and signs
indicative of differentiation. Oncogene 7:2303–13
Becker D, Meier CB, Herlyn M (1989) Proliferation of human-malignant
melanomas is inhibited by antisense oligodeoxynucleotides targeted
against basic fibroblast growth factor. EMBO J 8:3685–91
Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene
expression requires binding of the amyloid precursor protein intracel-
lular domain to its promoter: implications for Alzheimer disease. EMBO
Rep 10:94–100
Bradbury J (2005) RNA interference: new drugs on the horizon. Drug Discov
Today 10:1266–7
Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B et al.
(1993) A novel zinc(II)-binding site modulates the function of the beta A4
amyloid protein precursor of Alzheimer0s disease. J Biol Chem
268:16109–12
Culicchia F, Cui JG, Li YY, Lukiw WJ (2008) Upregulation of beta-amyloid
precursor protein expression in glioblastoma multiforme. Neuroreport
19:981–5
Fischer DF, van Dijk R, Sluijs JA, Nair SM, Racchi M, Levelt CN et al. (2005)
Activation of the Notch pathway in Down syndrome: cross-talk of Notch
and APP. FASEB J 19:1451–8
Gralle M, Botelho MM, de Oliveira CL, Torriani I, Ferreira ST (2002) Solution
studies and structural model of the extracellular domain of the human
amyloid precursor protein. Biophys J 83:3513–24
Gralle M, Ferreira ST (2007) Structure and functions of the human amyloid
precursor protein: the whole is more than the sum of its parts. Prog
Neurobiol 82:11–32
Hansel DE, Rahman A, Wehner S, Herzog V, Yeo CJ, Maitra A (2003)
Increased expression and processing of the alzheimer amyloid precursor
protein in pancreatic cancer may influence cellular proliferation. Cancer
Res 63:7032–7
Hoffmann J, Pietrzik CU, Kummer MP, Twiesselmann C, Bauer C, Herzog V
(1999) Binding and selective detection of the secretory N-terminal
domain of the Alzheimer amyloid precursor protein on cell surfaces.
J Histochem Cytochem 47:373–82
Hoffmann J, Twiesselmann C, Kummer MP, Romagnoli P, Herzog V (2000) A
possible role for the Alzheimer amyloid precursor protein in the
regulation of epidermal basal cell proliferation. Eur J Cell Biol 79:905–14
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH
et al. (1987) The precursor of Alzheimer0s disease amyloid A4 protein
resembles a cell-surface receptor. Nature 325:733–6
Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH et al. (2003) C-terminal
fragments of amyloid precursor protein exert neurotoxicity by inducing
glycogen synthase kinase-3 beta expression. FASEB J 17:1951–3
Kim SY, Kim MY, Mo JS, Park HS (2007) Notchl1 intracellular domain
suppresses APP intracellular domain-Tip60-Fe65 complex mediated
signaling through physical interaction. Biochim Biophys Acta
1773:736–46
Kirfel G, Borm B, Rigort A, Herzog V (2002) The secretory beta-amyloid
precursor protein is a motogen for human epidermal keratinocytes.
Eur J Cell Biol 81:664–76
Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel
precursor of Alzheimers-disease amyloid protein shows protease
inhibitory activity. Nature 331:530–2
Ko SY, Lin SC, Chang KW, Wong YK, Liu CJ, Chi CW et al. (2004) Increased
expression of amyloid precursor protein in oral squamous cell
carcinoma. Int J Cancer 111:727–32
Kong GK, Adams JJ, Harris HH, Boas JF, Curtain CC, Galatis D et al. (2007)
Structural studies of the Alzheimer0s amyloid precursor protein copper-
binding domain reveal how it binds copper ions. J Mol Biol 367:148–61
Krause K, Karger S, Sheu SY, Aigner T, Kursawe R, Gimm O et al. (2008)
Evidence for a role of the amyloid precursor protein in thyroid
carcinogenesis. J Endocrinol 198:291–9
Kummer C, Wehner S, Quast T, Werner S, Herzog V (2002) Expression and
potential function of beta-amyloid precursor proteins during cutaneous
wound repair. Exp Cell Res 280:222–32
Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M et al.
(1999) Constitutive and regulated alpha-secretase cleavage of
Alzheimer0s amyloid precursor protein by a disintegrin metalloprotease.
Proc Natl Acad Sci USA 96:3922–7
Li HL, Roch JM, Sundsmo M, Otero D, Sisodia S, Thomas R et al. (1997)
Defective neurite extension is caused by a mutation in amyloid beta/A4
(A beta) protein precursor found in familial Alzheimer0s disease.
J Neurobiol 32:469–80
Lleo A, Berezovska O, Ramdya P, Fukumoto H, Raju S, Shah T et al. (2003)
Notch1 competes with the amyloid precursor protein for gamma-
secretase and down-regulates presenilin-1 gene expression. J Biol Chem
278:47370–5
Meng JY, Kataoka H, Itoh H, Koono M (2001) Amyloid beta protein precursor
is involved in the growth of human colon carcinoma cell in vitro and
in vivo. Int J Cancer 92:31–9
Narindrasorasak S, Lowery D, Gonzalezdewhitt P, Poorman RA, Greenberg
B, Kisilevsky R (1991) High-affinity interactions between the Alzheimers
beta-amyloid precursor proteins and the basement-membrane form of
heparan-sulfate proteoglycan. J Biol Chem 266:12878–83
Ninomiya H, Roch JM, Sundsmo MP, Otero DA, Saitoh T (1993) Amino acid
sequence RERMS represents the active domain of amyloid beta/A4
protein precursor that promotes fibroblast growth. J Cell Biol 121:879–86
www.jidonline.org 1409
MG Botelho et al.
APP Downregulation and Melanoma Differentiation
Oh SY, Ellenstein A, Chen CD, Hinman JD, Berg EA, Costello CE et al. (2005)
Amyloid precursor protein interacts with notch receptors. J Neurosci Res
82:32–42
Ponte P, Gonzalezdewhitt P, Schilling J, Miller J, Hsu D, Greenberg B et al.
(1988) A new A4-amyloid messenger-RNA contains a domain homo-
logous to serine proteinase-inhibitors. Nature 331:525–7
Quast T, Wehner S, Kirfel G, Jaeger K, De Luca M, Herzog V (2003) sAPP as a
regulator of dendrite motility and melanin release in epidermal
melanocytes and melanoma cells. FASEB J 17:1739–41
Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D et al. (1999)
Crystal structure of the N-terminal, growth factor-like domain of
Alzheimer amyloid precursor protein. Nat Struct Biol 6:327–31
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M
et al. (2008) Identification of cells initiating human melanomas. Nature
451:345–9
Siemes C, Quast T, Kummer C, Wehner S, Kirfel G, Muller U et al. (2006)
Keratinocytes from APP/APLP2-deficient mice are impaired in prolifera-
tion, adhesion and migration in vitro. Exp Cell Res 312:1939–49
Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K et al. (1994)
A heparin-binding domain in the amyloid protein-precursor of Alzhei-
mers-disease is involved in the regulation of neurite outgrowth.
J Neurosci 14:2117–27
Smith AP, Hoek K, Becker D (2005) Whole-genome expression profiling
of the melanoma progression pathway reveals marked molecular
differences between nevi/melanoma in situ and advanced-stage mela-
nomas. Cancer Biol Ther 4:1018–29
Tanzi RE, McClatchey AI, Lamperti ED, Villakomaroff L, Gusella JF, Neve RL
(1988) Protease inhibitor domain encoded by an amyloid protein-
precursor messenger-RNA associated with Alzheimers-disease. Nature
331:528–30
Telese F, Bruni P, Donizetti A, Gianni D, D0Ambrosio C, Scaloni A et al.
(2005) Transcription regulation by the adaptor protein Fe65 and the
nucleosome assembly factor SET. EMBO Rep 6:77–82
von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM et al. (2004)
The APP intracellular domain forms nuclear multiprotein complexes and
regulates the transcription of its own precursor. J Cell Sci 117:4435–48
Wang YP, Rao U, Mascari R, Richards TJ, Panson AJ, Edington HD et al.
(1996) Molecular analysis of melanoma precursor lesions. Cell Growth
Differ 7:1733–40
Wehner S, Siemes C, Kirfel G, Herzog V (2004) Cytoprotective function of
sAPP alpha in human keratinocytes. Eur J Cell Biol 83:701–8
Zhang YW, Wangt RS, Liu Q, Zhang H, Liao FF, Xu HX (2007) Presenilin/
gamma-secretase-dependent processing of beta-amyloid precursor pro-
tein regulates EGF receptor expression. Proc Natl Acad Sci USA
104:10613–8
Zhuang LQ, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF et al.
(2007) Mcl-1, Bcl-XL and Stat3 expression are associated with
progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease
during progression of melanoma. Mod Pathol 20:416–26
1410 Journal of Investigative Dermatology (2010), Volume 130
MG Botelho et al.
APP Downregulation and Melanoma Differentiation
